BNTC Benitec Biopharma Inc

Price (delayed)

$11.09

Market cap

$380.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.01

Enterprise value

$196.94M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It ...

Highlights
The debt has contracted by 11% from the previous quarter and by 9% YoY
The equity has soared by 88% YoY but it has contracted by 2.2% from the previous quarter
BNTC's net income is down by 44% year-on-year but it is up by 5% since the previous quarter
The company's quick ratio fell by 16% QoQ

Key stats

What are the main financial stats of BNTC

BNTC stock price

How has the Benitec Biopharma stock price performed over time
Intraday
6.63%
1 week
-4.07%
1 month
-8.95%
1 year
-28.38%
YTD
-17.67%
QTD
4.13%

Financial performance

How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$53.94M
Net income
-$48.88M
Gross margin
N/A
Net margin
N/A
BNTC's net income is down by 44% year-on-year but it is up by 5% since the previous quarter
The operating income has declined by 44% year-on-year but it rose by 3.1% since the previous quarter

Price vs fundamentals

How does BNTC's price correlate with its fundamentals

Growth

What is Benitec Biopharma's growth rate over time

Valuation

What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
2.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The equity has soared by 88% YoY but it has contracted by 2.2% from the previous quarter
BNTC's P/B is 44% below its 5-year quarterly average of 3.5 and 33% below its last 4 quarters average of 2.9

Efficiency

How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has increased by 27% YoY and by 20% QoQ
Benitec Biopharma's ROA has increased by 23% YoY and by 19% from the previous quarter

Dividends

What is BNTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BNTC.

Financial health

How did Benitec Biopharma financials performed over time
The company's total assets has surged by 78% YoY
Benitec Biopharma's total liabilities has plunged by 52% YoY but it has increased by 10% from the previous quarter
The debt is 100% less than the equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The equity has soared by 88% YoY but it has contracted by 2.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.